Bioventix PLC - London-based biotechnology company - Says that it had a slow start to the financial year that ended June 30. Says that it registered an improvement in the second half and anticipates that its trading results as a whole will "likely" be significantly ahead of market expectations. Attributes the improvement to a degree of recovery from the pandemic woes it experienced since early 2020. "We hope that this recovery will prove to be sustained and long-lasting," the company says.
Current stock price: 3,350.00 pence, up 6.4% on Wednesday
12-month change: down 13%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Bioventix (BVXP)